Insmed | INSM

Stock Price
145.10
Daily Change
2.57 1.80%
Monthly
30.42%
Yearly
104.25%
Q3 Forecast
143.90

Peers Price Chg Day Year Date
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
DBV Technologies 8.97 -0.25 -2.75% 124.12% Sep/05
Dynavax Technologies 10.06 0.08 0.80% -8.79% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Insmed traded at $145.10 this Friday September 5th, increasing $2.57 or 1.80 percent since the previous trading session. Looking back, over the last four weeks, Insmed gained 30.42 percent. Over the last 12 months, its price rose by 104.25 percent. Looking ahead, we forecast Insmed to be priced at 143.90 by the end of this quarter and at 140.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.